Before promotion of the registry, referral rates for patients with PSA values ≥ 0.05 to < 0.1 ng/mL and ≥ 0.1 to < 0.2 ng/mL were 35% and 65%, respectively. After promotion of the registry, referral ...

A meta-analysis involving more than 6000 men suggested that adding hormone therapy (HT) to radiation after radical prostatectomy improves overall survival (OS) in those with higher pre-radiation ...

The phase 2/3 NRG GU002 trial (NCT03070886) evaluated whether adding 6 cycles of docetaxel after radiation and androgen ...

SAVE: A multicenter randomized phase 2 trial of salvage radiotherapy (SRT) with androgen-deprivation therapy (ADT) versus apalutamide (Apa) for biochemical progression after radical prostatectomy (RP) ...

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that treatment is working. A recent real-world study indicates that ...

Men with high-risk prostate cancer have a higher likelihood of residual disease after prostatectomy and may require radiation ...

Prostate cancer has a well-earned reputation for being one of the more trackable malignancies in medicine. Since the mid-1980s, a single blood test measuring prostate-specific antigen, or PSA, has ...

Prostate cancer is common. About 200 in every 1,000 Australian men will be told they have prostate cancer by the age of 85. But the chance of dying from it is much lower: around 18 in 1,000 cases.

SBRT after radical prostatectomy without ADT improves prostate cancer BCRFS and appears to be a viable alternative to conventionally fractionated radiation therapy, a phase 2 trial finds. After ...